Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin as Adjuvant Therapy in Esophageal Squamous Cell Carcinoma
NCT03900871Phase 1Unknown
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Apr 2019
- Primary completion
- Apr 2020
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aspirin in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Disease-Free Survival at 5 years. Status: unknown.
02
Drugs
aspirin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03900871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03900871.